Intercept’s NASH Approval Timeline Shuffled Again With FDA Delay

 
• By Joseph Haas

The company said a planned 9 June advisory committee to review the NDA for obeticholic acid in NASH has been postponed a second time, which means OCA likely will not be approved by 26 June.

Business time concept as a group of running businessmen and businesswomen using a giant clock to cross over a cliff as a bridge as a metaphor for schedule and appointment speed as a 3D illustration.
Intercept's timeline for OCA approval in NASH remains uncertain

More from New Products

More from Scrip